Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

202229 citationsJournal Articlegold Open Access

Authors

Lavinia Davidescu · University of Oradea

G. Ursol

Oleksii Korzh · Kharkiv Medical Academy of Postgraduate Education

Vikrant Deshmukh

L. M. Kuryk · National Academy of Medical Sciences of Ukraine

Monja-Marie Nortje

Olga Godlevska · Kharkiv Medical Academy of Postgraduate Education

Gilles Devouassoux · Université Claude Bernard Lyon 1

Abstract

Orally administered masitinib reduces the risk of asthma exacerbations in severe asthma patients, with an acceptable safety profile. Masitinib may potentially provide a new treatment option for oral corticosteroid-dependent severe asthma.

Topics & Keywords

Asthma and respiratory diseases IL-33, ST2, and ILC Pathways Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Asthma and Allergy

Volume Volume 15, pp. 737-747

DOI: 10.2147/jaa.s337284

Field-Weighted Citation Impact: 2.83